CHIME co-founder Correll to retire

Co-founder and former president and CEO of the College of Healthcare Information Management Executives (CHIME) Richard A. Correll will retire on June 30, after 23 years. Correll has been serving as the organization's chief operating officer and senior strategic advisor since April 2013 following the appointment of CEO Russell P. Branzell.

Correll championed the emergence of the chief information officer (CIO) in healthcare and has led the CHIME organization since it was created more than two decades ago. "My years serving CHIME have been a privilege and the most rewarding of my career," said Correll in a release. "With the indispensable support of our members, board and staff, the organization has become a recognized leader and advocate for the CIO role and the effective use of information management to improve patient care quality and safety.

Correll, along with prominent healthcare and vendor executives, formed CHIME in 1992, enlisting 192 charter members in the first year, led by founding board chair John Glaser, PhD. While serving on the HIMSS board in the 1980s, Correll identified the need for a professional organization dedicated to the development of the emerging top healthcare IT executives taking on the new title of CIO. Today, CHIME has grown to more than 1,500 members and 150 Foundation firm supporters.

A native of Ann Arbor, Mich., Correll earned an undergraduate degree in industrial engineering from the University of Michigan and an MBA from Wayne State University.


 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.